Specialist GP Nikki Vadgama provides some tips to make your next paediatric eczema consult easier. She includes a review of new guidelines, resources, websites and medications for paediatric eczema management
Two’s a party: Gonorrhoea treatment needs antimicrobial stewardship
Two’s a party: Gonorrhoea treatment needs antimicrobial stewardship
![2 sign](/sites/default/files/styles/cropped_image_16_7_/public/2022-03/2_CR_Natasha_Polyakova_on_Unsplash.jpg?itok=bXT6oeoe)
Here at New Zealand Doctor Rata Aotearoa we are on our summer break! While we're gone, check out Summer Hiatus: Stories we think deserve to be read again! This article was first published on 30 March 2022.
Sexual health specialist Massimo Giola explains the rationale behind the gonorrhoea treatment recommendations outlined in the new Aotearoa New Zealand STI Management Guidelines for use in primary care
- The international guidelines regarding the treatment of gonorrhoea are in a state of flux.
- The UK, US, Europe and Australia all have different recommendations.
- The new Aotearoa New Zealand STI Management Guidelines for use in primary care made a compromise based on limited local data about antibiotic resistance.
- We need to start applying good antimicrobial stewardship principles to STI treatment as well – for example, by avoiding using more antibiotics than necessary and keeping the spectrum narrow but sufficient for the infection(s) we are treating.
This article has been endorsed by the RNZCGP and has been approved for up to 0.25 CME credits for continuing professional development purposes (1 credit per learning hour). To claim your credits, log in to your RNZCGP dashboard to record this activity in the CME component of your CPD programme.
Nurses may also find that reading this article and reflecting on their learning can count as a professional development activity with the Nursing Council of New Zealand (up to 0.25 PD hours).
The sexual health nurse comes to see me, “Doctor, just a quick question before you start your clinic, please.” My readers should know the drill by now – deep breath, then, “Sure, fire away.”
“Do you remember the woman last week with vaginal discharge who we treated empirically for bacterial vaginosis while the swabs were pending? Well, they came back positive for both Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG)”.
My personal record is someone who had five different sexually transmitted infections at the same time (CT, NG, Trichomonas vaginalis, a herpes simplex virus type 2 flare, and secondary syphilis), so it can’t be any worse than that.
The sexual health nurse continues, “I am calling her back for treatment today. I was reading the new guidelines, but I’m a bit confused – before, I would have given her just ceftriaxone 500mg plus azithromycin 1g for NG, and we were told that would take care of CT as well. But now that doxycycline is recommended for CT rather than azithromycin, what should I do? Give her three antibiotics – ceftriaxone, azithromycin and doxycycline?”
You will know my answer by the end of the article.
Optimising the dose of one antibiotic to spare an unnecessary one is definitely one of the cornerstones of antimicrobial stewardship
The sexual health nurse is not the only one who is a bit confused. Unlike CT, NG is a master in the art of developing resistance to antibiotics, so much so that the state of untreatable disease due to a lack of effective antimicrobials is actually a possibility if we do not use carefully the few options we have left.
Unfortunately, international coordination is patchy; hence, different jurisdictions are opting for diverse solutions for NG infections:
- The British Association for Sexual Health and HIV now recommends ceftriaxone 1g monotherapy (bashh.org/guidelines).
- The US Centers for Disease Control and Prevention recommend ceftriaxone 500mg monotherapy, but ceftriaxone 1g if body weight is >150kg (tinyurl.com/CDCgonococcal).
- The European guideline recommends ceftriaxone 1g plus azithromycin 2g, or ceftriaxone 1g monotherapy only in certain (essentially specialist) settings (Int J STD AIDS 2020 29:956462420949126).
- In Australia, ceftriaxone 500mg plus azithromycin 1g (but azithromycin 2g for pharyngeal infections) is recommended (sti.guidelines.org.au).
When we (the New Zealand Sexual Health Society) approached this topic, we had very robust discussions, also because the New Zealand data on NG antibiotic resistance are very patchy and skewed towards specific subsets.
Essentially, primary care testing for NG is limited to PCR, which does not (yet) give the antibiotic susceptibilities. Therefore, only patients presenting to sexual health clinics (which are limited in number and coverage of the motu) also get a swab for culture and susceptibilities. This introduces a very significant bias towards the major cities and men who have sex with men in our antibiotic resistance data.
The conclusion of our discussions was, for now (subject to early review if and when more data become available), to keep recommending ceftriaxone 500mg plus azithromycin 1g stat for the majority of NG cases, but in the case of NG/CT coinfections, to move to ceftriaxone 1g for NG plus doxycycline 100mg twice daily for seven days for CT (click on “gonorrhoea” at sti.guidelines.org.nz).
This approach gives us confidence that:
- NG is effectively covered by the increased ceftriaxone dose, as per British guidelines
- CT is optimally covered by doxycycline for seven days, which is superior to azithromycin in many circumstances (see “Sexual health”, New Zealand Doctor, 2 February)
- some good antimicrobial stewardship (AMS) principles have been introduced, as optimising the dose of one antibiotic to spare an unnecessary one is definitely one of the cornerstones of AMS.
If I can disclose a personal viewpoint (not representing NZSHS), my opinion was to bring this AMS principle to the extreme consequences, as the British guidelines did; hence, stepping up the ceftriaxone dose and getting rid of the azithromycin for NG monoinfections.
So, you should be able to guess my answer now. I advised to treat the woman with the NG/CT coinfection with two antibiotics rather than three – ceftriaxone 1g via intramuscular injection stat (diluted with 3.5ml lignocaine 1 per cent) plus doxycycline 100mg orally twice daily for seven days. Contact tracing and notification were already being done by the sexual health nurse.
Early test of cure at four weeks after treatment is now only recommended in specific scenarios: pregnancy or pharyngeal infection for NG, and pregnancy or rectal infection for CT. All other patients should be offered a test for reinfection at three months after treatment.
Are there any indications for doing NG culture and susceptibilities in primary care?
You need to discuss this with your local microbiology lab as they might have local policies and protocols. In general, the NZSHS recommends performing an NG culture regardless of the setting in these circumstances (sti.guidelines.org.nz/sexual-health-check):
Females (endocervical swab) – if suspected pelvic inflammatory disease, profuse cervical discharge, or a contact of an NG case.
Males (urethral swab) – if frank urethral discharge is present (the swab does not need to be inserted into the urethra as long as pus is easily accessible in the meatus).
Transgender and non-binary people – as per the genital organs that are present (ie, endocervical swab as above if there is a uterus and cervix, urethral swab as above if there is a penis).
Massimo Giola is an infectious disease and sexual health physician, and clinical lead of the sexual health services for Bay of Plenty and Lakes DHBs
You can use the Capture button below to record your time spent reading and your answers to the following learning reflection questions:
- Why did you choose this activity (how does it relate to your professional development plan learning goals)?
- What did you learn?
- How will you implement the new learning into your daily practice?
- Does this learning lead to any further activities that you could undertake (audit activities, peer discussions, etc)?